We now have the capability to engineer human chromosomes that could be used
to deliver therapeutic genes in gene therapy studies. These vectors have t
he advantages of being non-disruptive to the genome, non-immunogenic and ar
e capable of carrying very large genes with all their regulatory sequences.
What challenges lie ahead, and what future does this technology hold for g
ene therapy?